32 Members of Congress Show Support for Accelerated Approval of Eteplirsen
Posted by: Christine McSherry on July 18, 2013
Very pleased to say that the “Dear Colleague” letter is being sent to Dr. Janet Woodcock at the FDA – with signatures from 32 Congressmen. This is a great accomplishment that was made possible by the Duchenne community and our supporters. Our deepest gratitude to Congressmen Keating, Capuano and Bachus’ offices who truly stepped up to help with this important endeavor. Many thanks to Ryan Fischer – PPMD, for sending out a call to action to the community.
The momentum of the letter and the briefing sparked the interest of Senator Elizabeth Warren (D-MA). Senator Warren is currently gaining support on the Senate with another powerful letter to the FDA. The additional support from the Senate side speaks volumes to the need for this drug, and faster treatments for all those with Duchenne.
Our voice, the voice of those affected – is being heard, loud and clear.
See the signed letter here:
07.18.13 Woodcock FDA letter
Bookmark the permalink | Tagged dmd, duchenne, eteplirsen, fda, muscular dystrophy, sarepta
pdufa fda patient-directed drug development patient perspectives duchenne muscular dystrophy harrison's fund duchenne allinace duchenne research alliance international invitation meeting duchenne muscular dystophy dmd treatment exon skipping sarepta eteplirsen dmd Permissible Risk Patient Perspective Duchenne Alliance PDUFA-V Fast Track Accelerated Approval Priority Review IND NDA Breakthrough therapy exon-skipping Duchenne muscular dystrophy collaboration rigorous review higher resolution. duchenne advocacy treatments pfizer children's hospital boston srpt $srpt jett foundation gower test biotech cambridge becker forbes healthcare rare disease new york times boston daily news prosensa moms morpholinos team community congress race to yes obama washington dc racetoyes washington white house petition fox business fox news stossel willis report government